Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1489-1492

  Nakai, Yousuke ^a   Isayama, Hiroyuki ^a   Ijichi, Hideaki ^a   Sasaki, Takashi ^a   Kogure, Hirofumi ^a   Yagioka, Hiroshi ^a   Miyabayashi, Koji ^a   Mizuno, Suguru ^a   Yamamoto, Keisuke ^a   Mouri, Dai ^a   Kawakubo, Kazumichi ^a   Yamamoto, Natsuyo ^a   Hirano, Kenji ^a   Sasahira, Naoki ^a   Tateishi, Keisuke ^a   Tada, Minoru ^a   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD PRESSURE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTIMETABOLITES, ANTINEOPLASTIC; BENZIMIDAZOLES; BLOOD PRESSURE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TETRAZOLES;

EID: 84864310711     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02311.x     Document Type: Article

References (29)

1. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-13.
2. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25.
3. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-6.
4. Philip PA, Benedetti J, Corless CL et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28: 3605-10.
5. Kindler HL, Niedzwiecki D, Hollis D et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28: 3617-22.
6. Kindler HL, Ioka T, Richel DJ et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12: 256-62.
7. Lever AF, Hole DJ, Gillis CR et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
8. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29: 1675-84.
9. Khakoo AY, Sidman RL, Pasqualini R, Arap W. Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 2008; 68: 9112-5.
10. Noguchi R, Yoshiji H, Ikenaka Y et al. Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities. Oncol Rep 2009; 22: 355-60.
11. Amaya K, Ohta T, Kitagawa H et al. Angiotensin II activates MAP kinase and NF-kappaB through angiotensin II type I receptor in human pancreatic cancer cells. Int J Oncol 2004; 25: 849-56.
12. Gong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking Angiotensin II Type 1 Receptor triggers Apoptotic cell death in human pancreatic cancer cells. Pancreas 2010; 39: 595-603.
13. Nakai Y, Isayama H, Ijichi H et al. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 2010; 103: 1644-8.
14. Mc Menamin UC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control 2012; 23: 221-30.
15. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
16. Ijichi H, Chytil A, Gorska AE et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006; 20: 3147-60.
17. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-402.
18. Sjolie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-93.
19. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-36.
20. Bangalore S, Kumar S, Kjeldsen SE et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
21. Chang CH, Lin JW, Wu LC, Lai MS. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011; 29: 3001-7.
22. Itakura J, Ishiwata T, Friess H et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997; 3: 1309-16.
23. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000; 88: 2239-45.
24. Smith RA, Tang J, Tudur-Smith C, Neoptolemos JP, Ghaneh P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer 2011; 104: 1440-51.
25. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ. Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007; 204: 996-1005.
26. Ijichi H, Chytil A, Gorska AE et al. Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011; 121: 4106-17.
27. Olson P, Hanahan D. Cancer. Breaching the cancer fortress. Science 2009; 324: 1400-1.
28. Greene AS, Amaral SL. Microvascular angiogenesis and the renin-angiotensin system. Curr Hypertens Rep 2002; 4: 56-62.
29. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist. FEBS Lett 2001; 495: 197-200.